0A4P logo

NVN Liquidation LSE:0A4P Stock Report

Last Price

US$0.0008

Market Cap

US$30.0

7D

0%

1Y

-99.9%

Updated

02 May, 2024

Data

Company Financials

0A4P Stock Overview

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases.

0A4P fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

NVN Liquidation, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NVN Liquidation
Historical stock prices
Current Share Price€0.0008
52 Week High€1.28
52 Week Low€0.0001
Beta1.65
11 Month Change0%
3 Month Changen/a
1 Year Change-99.93%
33 Year Change-99.99%
5 Year Changen/a
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

0A4PGB PharmaceuticalsGB Market
7D0%-4.3%-0.9%
1Y-99.9%5.7%8.6%

Return vs Industry: 0A4P underperformed the UK Pharmaceuticals industry which returned 5.7% over the past year.

Return vs Market: 0A4P underperformed the UK Market which returned 1.9% over the past year.

Price Volatility

Is 0A4P's price volatile compared to industry and market?
0A4P volatility
0A4P Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement4.7%
10% most volatile stocks in GB Market9.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0A4P's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0A4P's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200690Scott Pleshawww.novan.com

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.

NVN Liquidation, Inc. Fundamentals Summary

How do NVN Liquidation's earnings and revenue compare to its market cap?
0A4P fundamental statistics
Market capUS$29.97
Earnings (TTM)-US$32.05m
Revenue (TTM)US$24.92m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4P income statement (TTM)
RevenueUS$24.92m
Cost of RevenueUS$24.45m
Gross ProfitUS$473.00k
Other ExpensesUS$32.52m
Earnings-US$32.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.14
Gross Margin1.90%
Net Profit Margin-128.61%
Debt/Equity Ratio-1,164.1%

How did 0A4P perform over the long term?

See historical performance and comparison